Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: Rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex)

Contemporary Clinical Trials

Volumn 30, Issue 1, 2009, Pages 97-101

  Ueshima, Kenji ^a   Oba, Koji ^a   Yasuno, Shinji ^a   Fujimoto, Akira ^a   Sato, Tosiya ^b   Fukiyama, Koshiro ^c   Azuma, Junichi ^d   Ogihara, Toshio ^e   Saruta, Takao ^f   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^c Japan Seaman's Relief Association Moji Hospital   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e OSAKA GENERAL MEDICAL CENTER   (Japan)

^f School of Medicine Graduate School of Medicine   (Japan)

Author keywords

Amlodipine; Candesartan; Cardiovascular events; CASE J; Diabetes mellitus

Indexed keywords

AMLODIPINE; CANDESARTAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; TETRAZOLES;

EID: 57549096734     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2008.09.006     Document Type: Article

References (19)

1. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium-antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 355 (2000) 1955-1964
2. Gueffiyer F., Boutitie F., Boissel J.P., et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomised controlled trials. Ann Intern Med 126 (1997) 761-767
3. Psaty B., Smith N., Siscovick D., et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 277 (1997) 739-745
4. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985) 335-371
5. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
6. Flather M., Yusuf S., Kober L., et al. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
8. Lindholm L.H., Ibsen H., Dahlöf B., et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
9. Julius S., Kjeldsen S.E., Weber M., et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
10. Fukui T., Rahman M., Hayashi K., et al. CASE-J Study Group. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertens Res 26 (2003) 979-990
11. Ogihara T., Nakao K., Fukui T., et al. For the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 51 (2008) 393-398
12. Elliott W.J., and Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369 (2007) 201-207
13. Kjeldsena S.E., Julius S., Manciac G., et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 24 (2006) 1405-1412
14. Verdecchia P., Reboldi G., Angeli F., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
15. Aksnes T.A., Kjeldsen S.E., Rostrup M., Omvik P., Hua T.A., and Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 50 (2007) 467-473
16. The Heart Outcome Prevention Evaluation Study Investigators. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
17. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE Study Extension. Circulation 112 (2005) 1339-1346
18. Zanchetti A., Julius S., Kjeldsen S., et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 24 (2006) 2163-2168
19. Death and DALY estimates for 2002 by cause for WHO Member States: Burden of Disease statistics. World Health Organization. (Accessed February 27, 2007, at http://www.who.int/entity/healthinfo/statistics/bodgbddeathdalyestimates.xls).